FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090914388> ?p ?o ?g. }

• W2090914388 endingPage "931" @default.
• W2090914388 startingPage "926" @default.
• W2090914388 abstract "Thymic carcinoma is a rare neoplasm that often disseminates or metastasizes. The role of chemotherapy in treating this malignancy is unclear. The purpose of the current study was to determine the efficacy and tolerability of a weekly chemotherapy regimen consisting of cisplatin, vincristine, doxorubicin, and etoposide (CODE) for the treatment of advanced thymic carcinoma.The authors retrospectively reviewed 18 patients with thymic carcinoma who were treated between 1996 and 2002. Twelve of these patients had unresectable advanced diseases and received weekly chemotherapy according to the CODE regimen. The CODE regimen consisted of cisplatin (25 mg/m(2), intravenously [i.v.]; weekly administration), vincristine (1 mg/m(2), i.v.; administered during Weeks 1, 2, 4, 6, and 8), doxorubicin (40 mg/m(2), i.v.; administered during Weeks 1, 3, 5, 7, and 9), and etoposide (80 mg/m(2), i.v.; administered for 3 days during Weeks 1, 3, 5, 7, and 9).The responses of all 12 patients to the CODE regimen were assessed. A partial response was achieved in 5 patients, and the overall response rate was 42%. Only one patient experienced disease progression. The median progression-free survival period was 5.6 months (range, 2-39 months). The overall survival period ranged from 6 to 79 months, with a median survival period of 46 months. Based on the Kaplan-Meier method, the estimated 1-year and 2-year survival rates were 80% and 58%, respectively. The most common side effects were hematologic toxicities, and only mild nonhematologic toxicities were experienced.Weekly chemotherapy treatments according to the CODE regimen were effective and tolerated by patients with advanced thymic carcinoma." @default.
• W2090914388 created "2016-06-24" @default.
• W2090914388 creator A5000589488 @default.
• W2090914388 creator A5018607947 @default.
• W2090914388 creator A5033435047 @default.
• W2090914388 creator A5034162457 @default.
• W2090914388 creator A5037461196 @default.
• W2090914388 creator A5043607755 @default.
• W2090914388 creator A5046015782 @default.
• W2090914388 creator A5052865562 @default.
• W2090914388 creator A5083077229 @default.
• W2090914388 creator A5091584502 @default.
• W2090914388 date "2003-08-20" @default.
• W2090914388 modified "2023-10-06" @default.
• W2090914388 title "Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma" @default.
• W2090914388 cites W1868305875 @default.
• W2090914388 cites W1881109350 @default.
• W2090914388 cites W1909030710 @default.
• W2090914388 cites W1993584339 @default.
• W2090914388 cites W1994303805 @default.
• W2090914388 cites W2018425439 @default.
• W2090914388 cites W2023688278 @default.
• W2090914388 cites W2023937848 @default.
• W2090914388 cites W2023967320 @default.
• W2090914388 cites W2038518075 @default.
• W2090914388 cites W2042515268 @default.
• W2090914388 cites W2043855663 @default.
• W2090914388 cites W2053244130 @default.
• W2090914388 cites W2083719902 @default.
• W2090914388 cites W2089396628 @default.
• W2090914388 cites W2128501533 @default.
• W2090914388 cites W2140689138 @default.
• W2090914388 cites W2165581959 @default.
• W2090914388 cites W2465412048 @default.
• W2090914388 cites W416132280 @default.
• W2090914388 cites W4293241248 @default.
• W2090914388 doi "https://doi.org/10.1002/cncr.11606" @default.
• W2090914388 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12942558" @default.
• W2090914388 hasPublicationYear "2003" @default.
• W2090914388 type Work @default.
• W2090914388 sameAs 2090914388 @default.
• W2090914388 citedByCount "80" @default.
• W2090914388 countsByYear W20909143882012 @default.
• W2090914388 countsByYear W20909143882013 @default.
• W2090914388 countsByYear W20909143882014 @default.
• W2090914388 countsByYear W20909143882015 @default.
• W2090914388 countsByYear W20909143882016 @default.
• W2090914388 countsByYear W20909143882017 @default.
• W2090914388 countsByYear W20909143882018 @default.
• W2090914388 countsByYear W20909143882019 @default.
• W2090914388 countsByYear W20909143882021 @default.
• W2090914388 countsByYear W20909143882022 @default.
• W2090914388 countsByYear W20909143882023 @default.
• W2090914388 crossrefType "journal-article" @default.
• W2090914388 hasAuthorship W2090914388A5000589488 @default.
• W2090914388 hasAuthorship W2090914388A5018607947 @default.
• W2090914388 hasAuthorship W2090914388A5033435047 @default.
• W2090914388 hasAuthorship W2090914388A5034162457 @default.
• W2090914388 hasAuthorship W2090914388A5037461196 @default.
• W2090914388 hasAuthorship W2090914388A5043607755 @default.
• W2090914388 hasAuthorship W2090914388A5046015782 @default.
• W2090914388 hasAuthorship W2090914388A5052865562 @default.
• W2090914388 hasAuthorship W2090914388A5083077229 @default.
• W2090914388 hasAuthorship W2090914388A5091584502 @default.
• W2090914388 hasConcept C126322002 @default.
• W2090914388 hasConcept C141071460 @default.
• W2090914388 hasConcept C143998085 @default.
• W2090914388 hasConcept C197934379 @default.
• W2090914388 hasConcept C2776349617 @default.
• W2090914388 hasConcept C2776694085 @default.
• W2090914388 hasConcept C2776755627 @default.
• W2090914388 hasConcept C2778119113 @default.
• W2090914388 hasConcept C2778336483 @default.
• W2090914388 hasConcept C2778375690 @default.
• W2090914388 hasConcept C2779429289 @default.
• W2090914388 hasConcept C2781303535 @default.
• W2090914388 hasConcept C2781413609 @default.
• W2090914388 hasConcept C71924100 @default.
• W2090914388 hasConcept C90924648 @default.
• W2090914388 hasConceptScore W2090914388C126322002 @default.
• W2090914388 hasConceptScore W2090914388C141071460 @default.
• W2090914388 hasConceptScore W2090914388C143998085 @default.
• W2090914388 hasConceptScore W2090914388C197934379 @default.
• W2090914388 hasConceptScore W2090914388C2776349617 @default.
• W2090914388 hasConceptScore W2090914388C2776694085 @default.
• W2090914388 hasConceptScore W2090914388C2776755627 @default.
• W2090914388 hasConceptScore W2090914388C2778119113 @default.
• W2090914388 hasConceptScore W2090914388C2778336483 @default.
• W2090914388 hasConceptScore W2090914388C2778375690 @default.
• W2090914388 hasConceptScore W2090914388C2779429289 @default.
• W2090914388 hasConceptScore W2090914388C2781303535 @default.
• W2090914388 hasConceptScore W2090914388C2781413609 @default.
• W2090914388 hasConceptScore W2090914388C71924100 @default.
• W2090914388 hasConceptScore W2090914388C90924648 @default.
• W2090914388 hasIssue "5" @default.
• W2090914388 hasLocation W20909143881 @default.
• W2090914388 hasLocation W20909143882 @default.
• W2090914388 hasOpenAccess W2090914388 @default.

• next